RIBOBODY

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 28 Jun 2024 filing date already counts against anyone who files later.

Record

Serial number

98623781

Mark type

Stylized text

Filed

28 Jun 2024

Published for opposition

07 Oct 2025

Attorney of record

Christina M. Licursi

Goods and services

• Class 001 — Chemicals: Chemicals for use in therapeutic product development and manufacturing processes in the medical field; Biological and chemical agents, namely, chemical preparations for scientific and research use; chemicals for use in biotherapeutics in the biochemical and chemical industries and excluding medical and veterinary purpose; biological preparations for use in industry and science; chemical agents, namely, chemical preparations for analyses in laboratories, other than for medical or veterinary purposes
• Class 005 — Pharmaceuticals: Pharmaceutical, therapeutic pharmaceuticals, and biopharmaceutical preparations and agents for the treatment of a variety of human and animal diseases and disorders, RNA-based therapeutic pharmaceuticals and therapeutic agents for the treatment of a variety of human and animal diseases and disorders; medical diagnostic reagents and assays for testing of bodily fluids and tissue samples for the treatment and diagnosis of human and animal diseases and disorders
• Class 042 — Scientific and technological services: Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of a variety of human and animal diseases and disorders; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and drug discovery services; pharmaceutical research and analysis services using machine learning analytics relating to pharmaceutical drug development; scientific research, pharmaceutical research, medical research, technical consultation, and product development for others in the field of biotechnology and development of pharmaceutical, therapeutic, and biopharmaceutical preparations and agents; custom RNA targeting and assay development for the treatment of a variety of human and animal diseases and disorders in the field of biotechnology; pharmaceutical drug development related to proteins, ribosomes, DNA and RNA

Owner

• Ribo Therapeutics Inc., New York, NY, US
• Ribo Therapeutics Inc., New York, NY, US

Prosecution history

• 02 Dec 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 07 Oct 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 07 Oct 2025 — PUBLISHED FOR OPPOSITION
• 01 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 04 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 28 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 28 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 28 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 28 May 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 28 May 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 28 Feb 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 28 Feb 2025 — NON-FINAL ACTION E-MAILED
• 28 Feb 2025 — NON-FINAL ACTION WRITTEN
• 23 Jan 2025 — ASSIGNED TO EXAMINER
• 22 Jan 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED